GILD - Gilead Corp Price/Earnings to Growth Ratio

Brandmark of Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD) leverages the expertise of elite virologists to develop life-saving medications. Revenues are based on HIV, hepatitis, and oncology therapies. Dominance in the antiviral sector provides the capital necessary for new developments. The ratio of valuation to profit dynamics demonstrates market cycles, where the 1.74 mark records this indicator, helping to determine the real value of assets without speculative noise.

Gilead (GILD): Price/Earnings to Growth Ratio from 07/04/2022 to 11/18/2026

Metric breakdowns and analytics for Gilead (GILD)

- share price and consensus valuation forecast:
- market capitalization statistics:
General company analysis:Gilead Sciences, Inc.
Signature product of Gilead Sciences

For biopharmaceutical leader Gilead Sciences, Inc. (GILD), which saves millions of people from HIV and hepatitis C, the PEG ratio serves as a measure of how effectively the company capitalizes on its innovations. This chart compares the current market multiple with earnings growth, where a value below one signals that the asset is undervalued relative to its expansion, thereby determining the business's fundamental margin of safety.